GSK hepatitis B drug secures FDA priority review
Related Companies
Related Indices
Related Sectors
By Iain Gilbert
Date: Tuesday 28 Apr 2026
LONDON (ShareCast) - (Sharecast News) - Pharmaceutical giant GSK said on Tuesday that the US Food and Drug Administration had accepted its new drug application for bepirovirsen for priority review, with the drug being assessed as a potential treatment for adults with chronic hepatitis B.
GSK said the therapy had also been granted breakthrough therapy designation, which follows its receipt of fast‑track status in February 2024, intended to speed reviews for treatments addressing serious unmet need.
The FTSE 100-listed firm stated the submission and breakthrough designation were backed by positive Phase III B‑Well 1 and B‑Well 2 results, where bepirovirsen delivered "statistically significant and clinically meaningful" functional‑cure rates and showed an "acceptable safety profile".
GSK noted that chronic hepatitis B affects more than 250m people worldwide and around 1.7m in the US, with current standard therapies often requiring lifelong treatment and delivering functional‑cure rates of roughly 1%.
As of 1020 BST, GSK shares were down 0.74% at 2,001p.
Reporting by Iain Gilbert at Sharecast.com
See latest RNS at Investegate
Free Membership To Digital Look
Discover the full range of Investor's Tools and Services from Digital Look - voted 'Best Research & Information Provider 2007' by Investors Chronicle.
En HeaderFooterDLYou are here: research